1. Home
  2. TBPH vs OPK Comparison

TBPH vs OPK Comparison

Compare TBPH & OPK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$13.86

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo OPKO Health Inc.

OPK

OPKO Health Inc.

HOLD

Current Price

$1.17

Market Cap

921.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TBPH
OPK
Founded
2013
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
921.2M
IPO Year
2013
2011

Fundamental Metrics

Financial Performance
Metric
TBPH
OPK
Price
$13.86
$1.17
Analyst Decision
Strong Buy
Buy
Analyst Count
5
5
Target Price
$18.50
$2.03
AVG Volume (30 Days)
782.6K
2.0M
Earning Date
05-07-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.88
N/A
Revenue
$15,386,000.00
$606,879,000.00
Revenue This Year
$70.90
N/A
Revenue Next Year
N/A
$4.76
P/E Ratio
$15.75
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.90
$1.11
52 Week High
$21.03
$1.86

Technical Indicators

Market Signals
Indicator
TBPH
OPK
Relative Strength Index (RSI) 27.74 42.54
Support Level $13.41 $1.12
Resistance Level $14.76 $1.27
Average True Range (ATR) 0.58 0.04
MACD -0.08 0.00
Stochastic Oscillator 11.29 25.00

Price Performance

Historical Comparison
TBPH
OPK

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About OPK OPKO Health Inc.

OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.

Share on Social Networks: